The clinical quality management system of advanced therapy medicinal products in the hospital setting: A scoping review
Molecular Therapy Methods & Clinical Development · 2025-06 · 33 (2) · 101485
DOI: 10.1016/j.omtm.2025.101485 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Therapy Methods & Clinical Development, 2025-06. Verfasst von Junnan Shi und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR 999078, China. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fund for the Development of Science and Technology, University of Macau.
Abstract (Originalsprache)
Advanced therapy medicinal products (ATMPs) require rigorous quality management to mitigate risks associated with their development and use in hospitals. This study aimed to identify guidelines, standards of practice, and practical experiences in ATMPs quality management in hospital settings. An integrative scoping review under PRISMA guidelines retrieved 14 studies from four databases, 144 quality management guidelines and standards, and risk management reports for approved ATMPs from three government agencies and six organizations. Thirteen models or programs of quality management practices for ATMPs were identified across 25 hospital-based settings in six countries. Major aspects of ATMPs included clinical quality and translation, logistics management, hospital preparation, and patient care. Primary goals of ATMPs management within hospitals involved regulatory compliance and accreditation with national and regional requirements and implementing and maintaining the standardized operational practices. Four priority actions to enhance the quality of ATMPs management were as follows: (1) risk-based procedures and strategies; (2) strengthening of the skills and knowledge of healthcare professionals and technical staff; (3) validation and maintenance of qualified storage, manufacturing, and delivery facilities; and (4) support for a documentation system. In summary, understanding key components of ATMPs management offers valuable insights for developing an adaptive quality management ecosystem supporting clinical translation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR 999078, China.
- Centre for Pharmaceutical Regulatory Sciences, University of Macau, Taipa, Macao SAR 999078, China.
- Department of Public Health and Medicinal Administration, Faculty of Health Sciences, University of Macau, Macao SAR 999078, China.
Förderung
- Fund for the Development of Science and Technology
- University of Macau
Zitieren
APA
Shi, J., Yang, J., Zheng, Y., Wong, P. H. H., Hu, H., & Ung, C. O. L. (2025). The clinical quality management system of advanced therapy medicinal products in the hospital setting: A scoping review. Molecular Therapy Methods & Clinical Development, 33(2), 101485. https://doi.org/10.1016/j.omtm.2025.101485
Vancouver
Shi J, Yang J, Zheng Y, Wong PHH, Hu H, Ung COL. The clinical quality management system of advanced therapy medicinal products in the hospital setting: A scoping review. Molecular Therapy Methods & Clinical Development. 2025;33(2):101485. doi:10.1016/j.omtm.2025.101485
BibTeX
@article{Shi2025,
author = {Shi, Junnan and Yang, Jinagya and Zheng, Yu and Wong, Phyllis Hio Hong and Hu, Hao and Ung, Carolina Oi Lam},
title = {The clinical quality management system of advanced therapy medicinal products in the hospital setting: A scoping review},
journal = {Molecular Therapy Methods & Clinical Development},
year = {2025},
volume = {33},
number = {2},
pages = {101485},
doi = {10.1016/j.omtm.2025.101485}
}
EUVIMED